tbuckley/cabot-search huggingface dataset:
Progress in treatment of advanced urothelial tract tumors.
Authors: A Yagoda
Journal: Journal of Clinical Oncology (1985)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1985.3.11.1448 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3903061 Progress in treatment of advanced urothelial tract tumors. A YagodaxA YagodaSearch for articles by this author https://doi.org/10.1200/JCO.1985.3.11.1448 First Page PDF © 1985 by American Society of Clinical Oncology
AB0793 Clinical Characteristics of Hip Arthritis in Patients with Ankylosing Spondylitis in Korea
Authors: Y.H. Eun, H. Jeong, E.-J. Park, J. Hwang, H. Kim, J. Lee, H.-S. Cha, E.-M. Koh
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> This study aimed to evaluate the clinical characteristics and associated factors of hip arthritis in patients with ankylosing spondylitis (AS). <h3>Methods</h3> A retrospective analysis evaluated 488 patients of AS with hip arthritis at a single tertiary hospital in South Korea. Hip arthritis was assessed by Bath Ankylosing Spondylitis Radiology Hip Index (BASRI-h) and the average joint space width of the hip joint at three distinct sites that are in between the acetabulum and femoral head at baseline and last visit of outpatient clinic. Clinical and laboratory characteristics were collected. <h3>Results</h3> Among 488 patients with AS, 60 (12.3%) patients had hip arthritis. Body mass index (BMI) and erythrocyte sedimentation rate (ESR) were associated with hip involvement in AS (OR 1.11, 95% CI 1.03 to 1.19, p=0.008 and OR 1.01, 95% CI 1.00 to 1.02, p=0.005, respectively). The mean X-ray follow-up duration was 81.4±35.7 months. During the follow-up period, ESR and C-reactive protein (CRP) decreased significantly and there was no significant radiographic change in the hip joints. Among 60 patients, 7 (11.7%) patients had radiographic progression of the hip joints and 5 (8.3%) patients had hip replacement surgery. The BMI tended to be higher in patients with radiographic progression of the hip joints than in those without (23.4±4.2 vs. 26.6±3.9, p=0.068). <h3>Conclusions</h3> Most of the patients with hip arthritis in AS had no significant radiographic progression during the follow-up period. BMI was associated with hip involvement in patients with AS. <h3>Disclosure of Interest</h3> None declared
Short report: 5-Aza-2'-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group
Authors: M. Clavel, S. Monfardini, S. Fossa, J. Smyth, J. Renard, S.B. Kaye
Journal: Annals of Oncology (1992)
Eye blink and schizophrenia: psychosis or tardive dyskinesia?
Authors: J R Stevens
Journal: American Journal of Psychiatry (1978)

The author found abnormalities of ocular movement including abnormal blink rate and blink reflex to glabellar tap in 34 of 44 medication-free schizophrenic patients. It is not clear whether these signs represent part of the pathology of schizophrenia or result from withdrawal of neuroleptic treatment.
Acquired Arteriovenous Fistula
Authors: Oren K Steinmetz, L P Palerme
Journal: New England Journal of Medicine (2004)

A 35-year-old man presented with high-output congestive heart failure. Fourteen years earlier, he had received a shrapnel wound to the left thigh in a car-bomb attack in Lebanon. As a consequence, a progressively enlarging pulsatile mass had developed in the left side of the groin. Angiography showed a large arteriovenous fistula involving the deep femoral artery and vein (Panel A, arrow). A computed tomographic scan showed a large, thrombosed false aneurysm associated with the fistula (Panel B, arrow); a shrapnel fragment was also present (arrowhead). At surgery, all inflow and outflow vessels associated with the fistula were ligated. After surgery, . . .
Women at a Disadvantage in Fluorouracil Treatment
Authors: Joseph Ciccolini, Gérard Milano
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
THU0220 Regisponserbio, Baseline Visit: Differences Between Prevalent and Incidents Cases
Authors: M. Moreno, X. Juanola, V. Navarro-Compan, M. Aparicio, A. Sellas, E. de Miguel, L. Linares, T. Clavaguera, P. Fernadez-Dapica, E. Cuende, M. Fernandez-Espartero, J. Gratacόs
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Disease registries are a very useful tool to clarify and analyze in clinical practice differences between patients regarding epidemiology, prognostic, therapeutic efficacy, quality of life and socio-economic characteristics. <h3>Objectives</h3> To evaluate the main differences at the beginning of the current biological therapy between the prevalent and incident patients included in REGISPONSERBIO. <h3>Methods</h3> REGISPONSERBIO is a Spanish multicenter (17), prospective registry (3 year-follow-up, with clinical controls every six months) of patients with axial SpA (ASAS criteria) under biological treatment. All patients included should be under biologic treatment and have a minimum data set necessary to achieve the main objectives planed for the registry. The inclusion period extended between September 2013 and December 2014. The registry included two groups of patients: a) prevalent cases (patients receiving biological treatment prior to baseline visit) b) incident cases (patients who started biological therapy at the inclusion in the registry). In all patients the following data was collected at baseline: age, disease and treatment duration, gender, HLA B27, Body Mass Index (BMI), BASDAI, BASFI, CRP, ESR, metrological data, ASQoL, WAPAI, extra-articular manifestations, comorbidities, radiological study, biological treatment at the time of inclusion in the registry and concomitant treatments. For this study, characteristics between prevalent and incident cases were compared using t-Student and chi-square tests. Results are shown as mean (standard deviation) or relative frequencies. <h3>Results</h3> This registry included 258 patients, 174 out of 258 (67%) were prevalent cases. The group of prevalent patients showed higher disease evolution: 15 (11) vs 8 (11) years (p&lt;0.001), higher proportion of males: 144 (83%) vs 57 (69%) (p=0.01), less proportion of non radiographic axial spondylarthritis: 6 (3%) vs 12 (14%) (p=0.001) and higher proportion of HLA-B27 positive 145 (84%) vs 57 (69%) although this latter result did not reach statistical significance (p=0.06). <h3>Conclusions</h3> The observed data suggest that the profile of patients starting biological therapy seems to be changing in the last years. <h3>Disclosure of Interest</h3> None declared
Massachusetts Department of Public Health
Authors: Alfred L. Frechette, Pearl K. Russo
Journal: New England Journal of Medicine (1982)

RISK FACTORS AND LIFE STYLE: A STATEWIDE HEALTH-INTERVIEW SURVEYCraig A. Lambert, PH.D., David R. Netherton, M.S., Lorenz J. Finison, PH.D., James N. Hyde, M.S., and Sharon J. Spaight, B.A."Life style" — the set of habitual behaviors adopted by personal choice — may ultimately account for over half the annual deaths in the United States.1 Clinical research has identified several choices of life style as risk factors for serious illness. Determining the prevalence of such behaviors may therefore assist in allocating resources for primary disease prevention. This study profiles the health-related habits of Massachusetts residents, as recorded by a . . .
Synaptophysin depletion and intraneuronal Aβ in organotypic hippocampal slice cultures from huAPP transgenic mice
Authors: Claire S. Harwell, Michael P. Coleman
Journal: Molecular Neurodegeneration (2016)

To date, there are no effective disease-modifying treatments for Alzheimer's disease (AD). In order to develop new therapeutics for stages where they are most likely to be effective, it is important to identify the first pathological alterations in the disease cascade. Changes in Aβ concentration have long been reported as one of the first steps, but understanding the source, and earliest consequences, of pathology requires a model system that represents all major CNS cell types, is amenable to repeated observation and sampling, and can be readily manipulated. In this regard, long term organotypic hippocampal slice cultures (OHSCs) from neonatal amyloid mice offer an excellent compromise between in vivo and primary culture studies, largely retaining the cellular composition and neuronal architecture of the in vivo hippocampus, but with the in vitro advantages of accessibility to live imaging, sampling and intervention. Here, we report the development and characterisation of progressive pathological changes in an organotypic model from TgCRND8 mice. Aβ1-40 and Aβ1-42 rise progressively in transgenic slice culture medium and stabilise when regular feeding balances continued production. In contrast, intraneuronal Aβ continues to accumulate in close correlation with a specific decline in presynaptic proteins and puncta. Plaque pathology is not evident even when Aβ1-42 is increased by pharmacological manipulation (using calpain inhibitor 1), indicating that soluble Aβ species, or other APP processing products, are sufficient to cause the initial synaptic changes. Organotypic brain slices from TgCRND8 mice represent an important new system for understanding mechanisms of Aβ generation, release and progressive toxicity. The pathology observed in these cultures will allow for rapid assessment of disease modifying compounds in a system amenable to manipulation and observation.
Enzymatic Activities of Isolated Amelanotic and Melanotic Granules of Mouse Melanomas and a Suggested Relationship to Mitochondria&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: H. G. duBuy, M. W. Woods, Dean Burk, Mary D. Lackey
Journal: JNCI Journal of the National Cancer Institute (1949)

Enzymatic Activities of Isolated Amelanotic and Melanotic Granules of Mouse Melanomas and a Suggested Relationship to Mitochondria Get access H. G. duBuy, H. G. duBuy Search for other works by this author on: Oxford Academic PubMed Google Scholar M. W. Woods, M. W. Woods Search for other works by this author on: Oxford Academic PubMed Google Scholar Dean Burk, Dean Burk Search for other works by this author on: Oxford Academic PubMed Google Scholar Mary D. Lackey Mary D. Lackey Laboratory of Physical Biology and National Cancer Institute, National Institutes of Health, Public Health Service, Federal Security Agency. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 9, Issue 4, February 1949, Pages 325–336, https://doi.org/10.1093/jnci/9.4.325 Published: 01 February 1949 Article history Received: 18 May 1948 Published: 01 February 1949
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)
Authors: Eric L. Simpson, Abhijit Gadkari, Margitta Worm, Weily Soong, Andrew Blauvelt, Laurent Eckert, Richard Wu, Marius Ardeleanu, Neil M.H. Graham, Gianluca Pirozzi, E. Rand Sutherland, Vera Mastey
Journal: Journal of the American Academy of Dermatology (2016)
AB0495 Subcutaneous Methotrexate Safety in RA Patients (Remarca Trial Materials)
Authors: G.I. Gridneva, Y. Muraviev, D. Karateev, E. Luchikhina
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Methotrexate (MT) – is one of most preferable disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients. <h3>Objectives</h3> Aim – prospective study of harm caused by subcutaneous MT to achieve target RA activity and inflammation control (within REMARCA trial protocol). <h3>Methods</h3> 237 RA patients (with RA duration ≤6 mo (very early RA) – 101, &gt;6 mo – 136) were administered subcutaneous MT (SC MT) as DMARD starting at 10 mg/week with further rapid dose increment up to 20–30 mg/week. All ITT (who received at least I MT injection) population was evaluated. Patients were monitored with monthly routine clinical, lab and instrumental examination, all adverse drug reactions (ADRs) were documented in a special standardized form by a physician. MT discontinuations (for up to 3 weeks, i.e. with total medication washout) and withdrawals were also registered. Randomly assigned 60 patients were filling questionnaires in order to better evaluate SC MT tolerability and patient9s willingness to inject the drug continuously. <h3>Results</h3> MT–associated ADRs were registered in 49 (21%) patients: in 30 (61%) with very early RA and in 19 (39%) with RA &gt;6 mo. Most common ADRs: increase of aminotransferases levels (ALT; 5,1%), (AST; 4,2%), nausea – 3,4%; post-dosing reactions (dizziness, BP increase) – 2,5%; alopecia – 2,1%; rash – 1,7%; injection site skin reactions in situ – 1,3%; infections requiring antibiotics or antiviral drugs, – 1,3%; leukopenia – 1,3%; less common: diarrhea – 0,8%; metallic taste in the mouth – 0,4%; remote from injection site soft tissue abscess/infiltrate – 0,4%. In 4,2% patients both MT-related and non-related ADRs led to SC drug withdrawal: rash (2,1%), post-dosing reactions (0,8%), nausea (0,4%), elevated transaminases (0,4%), leukopenia (0,4%). In these patients ADRs were not related RA duration. Only in 1% of patients SC MT was intolerable, while other patients classified SC MT as comfortable (42%) or tolerable (57%). 88% of responders were in favor of SC MT long-term use, the rest were either not willing (12%) or have not yet made their mind (1%). <h3>Conclusions</h3> ADRs associated with SC MT were registered in one of every 5 patients and led to withdrawal from SC MT in 4,2% RA patients. In 11% SC MT was discontinued due to ADRs, bat later restarted again. Obtained results allow to discuss the usefullnes of SC MT before administration of GEBA. This study has also established RA patients9 compliance with continuous use of SC MT. <h3>Disclosure of Interest</h3> None declared
Case report of withdrawal dyskinesia associated with amoxapine
Authors: R A Weller, W V McKnelly
Journal: American Journal of Psychiatry (1983)

The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects. Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.
Prevention of Venous Thrombosis and Pulmonary Embolism
Authors: L J Greenfield, T W Wakefield
Journal: JAMA (1986)

Transvenous Greenfield filter insertion is a safe and efficient mechanical means of protection against recurrent pulmonary thromboembolism both in the infrarenal and suprarenal positions. Long-term follow-up to 12 years has demonstrated a consistently high patency rate of 96%, which is independent of concomitant anticoagulant therapy. The incidence of recurrent embolism in patients with filters has not changed over time, and there has been no significant filter migration over prolonged periods of observation.
Behavioral aspects of panic disorder
Authors: I M Marks
Journal: American Journal of Psychiatry (1987)

The behavioral approach to panic disorder distinguishes between agoraphobia and nonsituational panic and emphasizes the handicap to the patient caused by avoidance of agoraphobic situations. Agoraphobia is a more viable label than panic disorder. Behavioral treatment consists of delineating the patient's agoraphobic avoidance and panic profile and developing a self-exposure program to produce habituation. Systematic exposure to agoraphobic situations is usually of durable efficacy, and the treatment requires little time from clinicians. Antidepressant drugs, which do not interfere with exposure, are a useful addition when dysphoria is present, but they can have troublesome side effects.
THU0481 Discovery of Potential Serum Biomarkers in Osteoarthritis Using Protein Arrays
Authors: L. Lourido, B. Ayoglu, F. Henjes, J.M. Schwenk, M. Fuentes, C. Ruiz-Romero, P. Nilsson, F.J. Blanco
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Osteoarthritis (OA) is the most common rheumatic disease. To date, the diagnostic methods of OA are very limited and low accurate to detect changes in the joint, what means to wait for a long time to get reliable information about the disease progression. Moreover, there are no available medications capable of halting its characteristic cartilage degradation. Therefore, there is a significant interest to find new biomarkers potentially useful for early diagnosis, prognosis and therapeutic monitoring. <h3>Objectives</h3> In the present study, we utilize different affinity proteomics approaches for profiling autoantibodies and proteins in a large number of serum samples from OA patients and compare this profile with that observed in control individuals and other rheumatic diseases. Our overall objective is to develop a novel diagnosis method for the high-throughput analysis of OA patients, applicable in clinical practice. <h3>Methods</h3> We analyzed a total of 960 serum samples from control individuals (Ctrl) and patients with osteoarthritis (OA), rheumatoid arthritis (RA) and psoriatic arthritis (PSA). On one hand, to characterize the autoantibody repertoire from each group of study, we used antigen arrays and NAPPA (Nucleic Acid Programmable Protein Arrays). In the first platform, a total of 3840 protein fragments were analysed and 373 were selected for further validation analysis. Using NAPPA, we studied autoantibodies towards 80 different proteins selected by their relevance in OA pathology. On the other hand, to characterize the different protein profile of these samples, 174 antibodies towards 78 different proteins included in Human Protein Atlas (HPA) were coupled to bead array and screened with the 960-sample set. <h3>Results</h3> Using antigen array and NAPPA, 15 autoantibodies were identified as potential candidates to distinguish between OA patients, RA patients and controls. In complementary efforts, using antibody arrays, we identified a panel of 12 serum proteins whose levels distinguish between OA patients and controls. Moreover, we identified 34 proteins significantly different between PSA and Ctrl, and a panel of 45 proteins, which distinguish between OA patients and PSA patients. <h3>Conclusions</h3> Broad-scaled protein profiling of autoantibody repertoires and protein levels in serum enables discovery of potential novel biomarkers in osteoarthritis. Using different protein array formats we have defined interesting marker candidates, which allow distinguishing serum samples from control individuals, OA patients and other rheumatic diseases. These proteins are now brought into the next level of verification where a new cohort of new serum samples will be utilized. <h3>Disclosure of Interest</h3> None declared
PTH-322 A single tertiary centre experience of t1 colorectal cancers – a retrospective analysis
Authors: R Peravali, T Naeem, J Wheeler
Journal: Gut (2015)

<h3>Introduction</h3> The management of T1 colorectal cancer remains controversial and not standardised. Surgical resection can offer cure in the majority of patients and provides appropriate lymph node staging and guides adjuvant treatment. Endoluminal excision has significantly reduced morbidity but risks undertreating undetected lymph node metastases. The aim of this study was to review practice in a single tertiary referral centre over a period of five years. <h3>Method</h3> A retrospective analysis of histology reports, radiology imaging, and electronic records of all confirmed T1 cancers identified on our pathology database was undertaken. Cases between December 2006 and December 2011 were included giving a minimum follow up of 3 years. <h3>Results</h3> There were a total of 71 (47 colon and 24 rectal) T1 cancers that were offered surgical resection. The median age at operation was 66 years (range 36–92). 10 patients (14%) were over the age of 80. Nodal metastases were present in 14 patients (20%). This was higher in rectal cancers than in colon cancers. (33% vs. 13%, p = 0.046). There was one sigmoid cancer staged as T1N2 following sigmoid resection. SM3 invasion and vascular invasion are significantly more likely to be associated with lymph node metastases. (p = 0.048 ad 0.002 respectively). No patients had local recurrences at 3 years. Three patients (4%) had distant metastases at 3 years. One patient had a node negative sigmoid cancer and the other two had rectal cancers one of which was node positive. The cancer specific mortality was 1.4% in this cohort. <h3>Conclusion</h3> In this series lymph node metastases are less common in T1 colonic tumours than in rectal cancers. However, 16 of 24 patients (67%) who underwent a rectal resection for T1 cancers had no evidence of lymph node involvement or vascular invasion. <h3>Disclosure of interest</h3> None Declared.
Virus of Avian Myeloblastosis. XI. Release of the Virus by Myeloblasts in Tissue Culture&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: G. S. Beaudreau, Caroline Becker, D. G. Sharp, J. C. Painter, J. W. Beard
Journal: JNCI Journal of the National Cancer Institute (1958)

Virus of Avian Myeloblastosis. XI. Release of the Virus by Myeloblasts in Tissue Culture2 G. S. Beaudreau, G. S. Beaudreau Department of Surgery, Duke University School of Medicine, Durham, North Carolina Search for other works by this author on: Oxford Academic PubMed Google Scholar Caroline Becker, Caroline Becker Department of Surgery, Duke University School of Medicine, Durham, North Carolina Search for other works by this author on: Oxford Academic PubMed Google Scholar D. G. Sharp, D. G. Sharp Department of Surgery, Duke University School of Medicine, Durham, North Carolina Search for other works by this author on: Oxford Academic PubMed Google Scholar J. C. Painter, J. C. Painter Department of Surgery, Duke University School of Medicine, Durham, North Carolina Search for other works by this author on: Oxford Academic PubMed Google Scholar J. W. Beard J. W. Beard Department of Surgery, Duke University School of Medicine, Durham, North Carolina Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 2, February 1958, Pages 351–381, https://doi.org/10.1093/jnci/20.2.351 Published: 01 February 1958 Article history Received: 29 July 1957 Published: 01 February 1958